Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03706833 · ClinicalTrials.gov registry record · NA

Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial

A NA study of Mitral Regurgitation and Functional Mitral Regurgitation, sponsored by Edwards Lifesciences.

Active
Registry status
NA
Development phase
1,247
Enrollment target
20
Study locations

NCT03706833: Active NA study of Mitral Regurgitation and Functional Mitral Regurgitation, sponsored by Edwards Lifesciences.

NCT03706833 is a NA study of Mitral Regurgitation and Functional Mitral Regurgitation that is active but no longer recruiting, run by Edwards Lifesciences. The registered enrollment target is 1,247 participants, above the 976-participant average among 26 other Mitral Regurgitation trials with a reported enrollment target (28% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03706833, a NA study of Mitral Regurgitation and Functional Mitral Regurgitation, is active but no longer recruiting, sponsored by Edwards Lifesciences.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
1,247 participants
Enrollment target
20
Study locations

Study Summary

To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with functional mitral regurgitation (FMR) on guideline directed medical therapy (GDMT)

Interventions

  • DEVICE Edwards PASCAL System
  • DEVICE Abbott Mitraclip System

Study Locations (20)

California

  • Scripps Memorial Hospital La Jolla - La Jolla
  • Cedars Sinai Medical Center - Los Angeles
  • UC Irvine - Orange
  • Sutter Medical Center-Sacramento - Sacramento
  • Sutter Bay Area - San Francisco
  • Kaiser Permanente San Francisco - San Francisco
  • University of California, San Francisco - San Francisco
  • Stanford University - Stanford
  • Los Robles Hospital and Medical Center - Thousand Oaks

Florida

  • The Cardiac and Vascular Institute Research Foundation - Gainesville
  • Mount Sinai - Miami Beach
  • NCH Rooney Heart Institute - Naples
  • AdventHealth Orlando - Orlando

Arizona

  • Banner University Medical Center - Phoenix
  • Abrazo Arizona Heart Hospital - Phoenix
  • TMC Healthcare - Tucson

Georgia

  • Piedmont Healthcare - Atlanta
  • Emory University Hospital and Emory University Hospital Midtown - Atlanta

Colorado

  • Medical Center of the Rockies - Loveland

District of Columbia

  • Medstar Washington Hospital Center - Washington D.C.

Trial Details

FieldValue
Enrollment Target 1,247 participants
Start Date 2018-11-30
Est. Completion 2031-06-30
Phase NA
Edwards Lifesciences

57 total trials

What the registry record for NCT03706833 still lists

NCT03706833 is an interventional study that assigns participants to a tested intervention. Its 1,247 participants enrollment target places it among the larger protocols in the corpus, above the 976-participant average among 26 other Mitral Regurgitation trials with a reported enrollment target (28% higher).

The record links to 4 conditions, with Mitral Regurgitation appearing as the primary indexed condition, and to 2 interventions - of which Edwards PASCAL System is the first listed.

NCT03706833 names 20 study sites across 6 states, led by California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT03706833 about?

NCT03706833 is a clinical study titled "Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial". To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with functional mitral regurgitati...

What is the current status of trial NCT03706833?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,247 participants. The study started on 2018-11-30. Estimated completion is 2031-06-30.

What conditions does trial NCT03706833 study?

This clinical trial studies the following conditions: Mitral Regurgitation, Functional Mitral Regurgitation, Mitral Insufficiency, Degenerative Mitral Valve Disease.

What interventions are being tested in trial NCT03706833?

The interventions under investigation include: Edwards PASCAL System (DEVICE), Abbott Mitraclip System (DEVICE).

Who is sponsoring clinical trial NCT03706833?

This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03706833 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Mitral Regurgitation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03706833's enrollment target sits among peer trials

1,247 3rd of 26 higher than 24 of 26 other Mitral Regurgitation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Mitral Regurgitation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02743858 · 1,250 participants

    Lymphedema Surveillance Study

  • NCT04670874 · 1,250 participants

    Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29

  • NCT04807868 · 1,250 participants

    AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)

  • NCT05995821 · 1,250 participants

    Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03706833, the US trial registry maintained by the National Library of Medicine. NCT03706833 (large enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.